MoonLake Immunotherapeutics
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLTX research report →
About the company
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis.
- CEO
- Jorge Santos da Silva
- IPO
- 2020
- Employees
- 100
- HQ
- Zug, CH
Price Chart
- Market Cap
- $1.40B
- P/E
- -4.88
- P/S
- 0.00
- P/B
- 5.32
- EV/EBITDA
- -4.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -85.61%
- ROIC
- -75.28%
- Revenue
- $0 · 0.00%
- Net Income
- $-227,318,000 · -91.13%
- EPS
- $-3.53 · -86.77%
- Op Income
- $-244,834,000
- FCF YoY
- -67.40%
- 52W High
- $62.75
- 52W Low
- $5.95
- 50D MA
- $18.23
- 200D MA
- $17.17
- Beta
- 1.04
- Avg Volume
- 1.08M
Get TickerSpark's AI analysis on MLTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Santos da Silva Jorge | sell | 47,775 |
| Jun 22, 26 | Bodenstedt Matthias | sell | 39,120 |
| Jun 17, 26 | BVF PARTNERS L P/IL | other | 22,195 |
| Jun 17, 26 | Bodenstedt Matthias | sell | 15,082 |
| Jun 18, 26 | Bodenstedt Matthias | sell | 2,794 |
| Jun 17, 26 | Phillips Andrew John | other | 22,195 |
| Jun 17, 26 | Loy Spike | other | 22,195 |
| Jun 17, 26 | Moukheibir Catherine | other | 22,195 |
| Jun 17, 26 | Xavier Ramnik | other | 22,195 |
| Jun 15, 26 | Reich Kristian | sell | 50,000 |
Our MLTX coverage
Recent articles, reports, and earnings notes.
No research on MLTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLTX report →Similar companies
Peers in the same neighborhood.